<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059081</url>
  </required_header>
  <id_info>
    <org_study_id>ML40990</org_study_id>
    <nct_id>NCT04059081</nct_id>
  </id_info>
  <brief_title>A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment</brief_title>
  <official_title>A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deok-Hwan Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is prospective, open-label, single arm observational study to assess efficacy of
      obinutuzumab plus chlorambucil (GC) chemotherapy in treatment naïve CLL, and prognostic
      impact of genetic alterations for CLL using NGS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2019</start_date>
  <completion_date type="Anticipated">July 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 8, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>3 years</time_frame>
    <description>iwCLL criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>3 years</time_frame>
    <description>No evidence of disease at the time of tumor assessment by NGS method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years</time_frame>
    <description>the time from first dose to documented disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>the time from first dose to death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>GC chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Before administration of GC chemotherapy, all patients must undergo pretreatment bone marrow biopsy. The pretreatment BM biopsy must include at least 1 long core biopsy samples and 10 cc of aspirate.
Obinutuzumab 1000mg fixed dose will be administered intravenously (Day 1,8,15 for cycle 1 and D1 for subsequent cycles). Chlorambucil 0.5mg/kg will be administered orally (D1,15 for all cycles).
28 days are considered as one cycle, and cycles will be repeated every 4-weeks for a total of 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Obinutuzumab is provided as single-use vials for intravenous administration only. Obinutuzumab 1000mg fixed dose will be administered Chlorambucil would be provided as oral tablet with dose of 0.5mg/kg
Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, until 6 cycles.</description>
    <arm_group_label>GC chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible subjects will be considered for inclusion in this study if they meet all of
             the following criteria:

               1. Newly diagnosed chronic lymphocytic leukemia

               2. Age≥ 70 years

               3. Satisfy the one of indications for starting treatment guideline

               1. Evidence of progressive marrow failure (anemia, thrombocytopenia)

               2. AIHA, thrombocytopenia refractory to steroids

               3. Massive (&gt;6cm, LCM) or symptomatic splenomegaly

               4. Massive nodes (&gt;10 cm) or symptomatic

               5. Progressive lymphocytosis

               6. 50% increase over 2 months or LDT &lt; 6 months

               7. Constitutional Symptoms : weight loss &gt; 10% in 6 months, significant fatigue,
                  fever &gt;38 over 2 weeks, night sweat &gt; 1month 4. ECOG performance status 0-2 5.
                  Total bilirubin ≤ 1.5 x ULN (upper limit of normal) 6. Aspartate aminotransferase
                  (AST) ≤ 5 x ULN, (ALT) ≤ 5 x ULN 7. Creatinine ≤ 3.0 x ULN 8. Provide informed
                  consent Ability to understand the purpose and risks of the study and provide
                  signed and dated informed consent and authorization to use protected health
                  information

        Exclusion Criteria:

          1. Unmet NGS samples by bone marrow biopsy or peripheral bloods at diagnosis

          2. Hairy cell leukemia or prolymphocytic leukemia

          3. Uncontrolled infection

          4. Therapy history with combined chemotherapy or biologic therapy prior to registration

          5. History of thromboembolic episodes ≤ 3 months prior to registration

          6. Active hepatitis B or C with uncontrolled disease

          7. Active other malignancy requiring treatment that would interfere with the assessments
             of response of the lymphoma to protocol treatment

          8. Any severe and/or uncontrolled medical conditions or other conditions that could
             adversely impact their ability to participate in the study

          9. Concurrent participation in another therapeutic clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Deok-Hwan Yang, M.D., Ph.D.</last_name>
    <email>drydh1685@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young-il Koh, M.D., Ph.D.</last_name>
    <email>snuhgo01@gmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>So-Young Lee, Nurse</last_name>
      <phone>82-61-379-7628</phone>
      <email>kaosin@naver.com</email>
    </contact>
    <investigator>
      <last_name>Deok-Hwan Yang, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.</citation>
    <PMID>29540348</PMID>
  </reference>
  <reference>
    <citation>Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.</citation>
    <PMID>24401022</PMID>
  </reference>
  <reference>
    <citation>Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. 2016 Mar;16(3):145-62. doi: 10.1038/nrc.2016.8. Review.</citation>
    <PMID>26911189</PMID>
  </reference>
  <reference>
    <citation>Herling CD, Klaumünzer M, Rocha CK, Altmüller J, Thiele H, Bahlo J, Kluth S, Crispatzu G, Herling M, Schiller J, Engelke A, Tausch E, Döhner H, Fischer K, Goede V, Nürnberg P, Reinhardt HC, Stilgenbauer S, Hallek M, Kreuzer KA. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood. 2016 Jul 21;128(3):395-404. doi: 10.1182/blood-2016-01-691550. Epub 2016 May 25.</citation>
    <PMID>27226433</PMID>
  </reference>
  <reference>
    <citation>Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.</citation>
    <PMID>30501481</PMID>
  </reference>
  <reference>
    <citation>Kim JA, Hwang B, Park SN, Huh S, Im K, Choi S, Chung HY, Huh J, Seo EJ, Lee JH, Bang D, Lee DS. Genomic Profile of Chronic Lymphocytic Leukemia in Korea Identified by Targeted Sequencing. PLoS One. 2016 Dec 13;11(12):e0167641. doi: 10.1371/journal.pone.0167641. eCollection 2016.</citation>
    <PMID>27959900</PMID>
  </reference>
  <reference>
    <citation>Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, Hess U, Vey N, Pignon JM, Braun T, Marolleau JP, Cahn JY, Chalandon Y, Lhéritier V, Beldjord K, Béné MC, Ifrah N, Dombret H; for GRAALL. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Sep 15;375(11):1044-53. doi: 10.1056/NEJMoa1605085.</citation>
    <PMID>27626518</PMID>
  </reference>
  <reference>
    <citation>Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20;28(24):3880-9. doi: 10.1200/JCO.2009.26.9456. Epub 2010 Jul 26.</citation>
    <PMID>20660823</PMID>
  </reference>
  <reference>
    <citation>Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, Kranzhöfer N, Rohrberg R, Söling U, Burkhard O, Westermann A, Goede V, Schweighofer CD, Fischer K, Fink AM, Wendtner CM, Brittinger G, Döhner H, Emmerich B, Hallek M; German CLL Study Group (GCLLSG). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009 Oct 15;114(16):3382-91. doi: 10.1182/blood-2009-02-206185. Epub 2009 Jul 15.</citation>
    <PMID>19605849</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chonnam National University Hospital</investigator_affiliation>
    <investigator_full_name>Deok-Hwan Yang</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

